← Eichor
Condition: Undifferentiated Type Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Undifferentiated Type

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type
NA · 1 location(s) · National Cancer Center, Korea · NCT04890171
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565
Toripalimab With Chemotherapy for Sinus Cancer
Phase 2 · 2 location(s) · Glenn J. Hanna · NCT06940180
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Phase 1/Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT03603405
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Ref
Phase 2 · 1 location(s) · Northwell Health · NCT02800486
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Princess Maxima Center for Pediatric Oncology · NCT04925609
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820
Implantable Microdevice In Primary Brain Tumors
EARLY_Phase 1 · 1 location(s) · Oliver Jonas · NCT04135807
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase 1/Phase 2 · 1 location(s) · University of Miami · NCT05956821
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06612827
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690
Lurbinectedin in FET-Fused Tumors
Phase 1/Phase 2 · 6 location(s) · Children's Hospital of Philadelphia · NCT05918640
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Phase 2 · 4 location(s) · Niels Junker · NCT05961761
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NA · 1 location(s) · Zhejiang Provincial People's Hospital · NCT07068542
Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Phase 2 · 10 location(s) · Institut Bergonié · NCT05182164
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe
Phase 3 · 257 location(s) · National Cancer Institute (NCI) · NCT06422806
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07181720
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.